What's next for anti-obesity and weight loss drugs?


Kara L. Marlatt, PhD, MPH, tells Contemporary OB/GYN® about the exciting new anti-obesity and weight loss drugs to watch for.

Kara L. Marlatt, PhD, MPH sat down with Contemporary OB/GYN® after her presentation at the North American Menopause Society on treating weight gain in menopause. Marlatt is an assistant professor of research at Pennington Biomedical Research Center at Louisiana State University in Baton Rouge, LA and specializes in healthy aging and metabolism.


  • 2.4-mg weekly subcutaneous injection
  • 15-17% weight loss


  • 15% to 17% weight loss

Cagrilintide + semaglutide

  • Cagrilintide is an amylin analog and it's combined with semaglutide
  • Anywhere from 20% to 25% weight loss


"There's also an exciting drug that's in Phase 2 trials that could also be an improvement. What those studies are showing so far is that with weight loss, there's actually a loss in fat mass. But more importantly, there's a retention, or there's a gain in fat-free mass. And so really, I think these newer cutting-edge drugs will do that very thing.

So with weight loss, you're not going to see the 75% fat mass loss, but you're also going to get the 25% fat free mass loss too. Instead, it's flipping. It's changing the game in that now you're not only going to be losing fat mass, but you might actually gain fat free mass, and so that's really good for just aging in general.

Those are the ones that are the most exciting ones that are coming down the pipeline that people should be looking for. I think the biggest thing is that physicians and patient-facing practitioners should really be patient, but very optimistic, that these drugs will become more readily available. It's really going to bridge this gap between what lifestyle intervention can do and what bariatric surgery can do. We're really getting closer to getting to what bariatric surgery can do."

Related Videos
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit: sutterhealth.org
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit: uclahealth.org.
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit: mayo.edu.
New data shows elinzanetant's efficacy in treating menopausal symptoms | Image Credit: uvahealth.com
Navigating vasomotor symptoms in breast cancer patients | Image Credit: menopausefoundationcanada.ca.
Learning what women prefer in STI preventive care
Why doxycycline PEP lacks clinical data for STI prevention in women
Revolutionizing menopause management: A deep dive into fezolinetant | Image Credit: uvahealth.com.
Hot flashes poorly impact sleep quality | Image Credit: intimmedicine.com
What's new in endometrium care? | Image Credit: nyulangone.org
Related Content
© 2024 MJH Life Sciences

All rights reserved.